

Edgar Filing: PHARMION CORP - Form 8-K

PHARMION CORP
Form 8-K
January 03, 2008

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 3, 2008

Pharmion Corporation
(Exact name of Registrant as specified in its charter)

Delaware	000-50447	84-1521333
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2525 28th Street, Boulder, Colorado	80301
(Address of principal executive offices)	(Zip Code)

720-564-9100
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the Registrant under any of the
following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
- =====

Edgar Filing: PHARMION CORP - Form 8-K

Item 8.01 Other Events.

On January 3, 2008, Pharmion Corporation announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired without the United States Federal Trade Commission requesting additional information with regard to Celgene Corporation's pending acquisition of Pharmion. The press release is attached hereto as an exhibit and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit 99.1 Press Release issued by Celgene Corporation and Pharmion Corporation, dated January 3, 2008

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 3, 2008

PHARMION CORPORATION

By: /s/ Steven N. Dupont

Name: Steven N. Dupont
Title: Executive Vice President
and General Counsel

EXHIBIT INDEX

Exhibit No. -----	Description -----
Exhibit 99.1	Press Release issued by Celgene Corporation and Pharmion Corporation, dated January 3, 2008